Pfizer Inc. will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025, building on the company's 20-years of work to help eliminate the world's leading infectious cause of blindness. Approximately 163 million people are at risk of developing the disease and this recommitment ensures that Pfizer, through the International Trachoma Initiative (ITI), will continue to provide trachoma endemic countries with donated antibiotics that are a critical component of the global strategy to eliminate this neglected tropical disease (NTD).
Pfizer's continued donation program will help accelerate significant progress made in the last decade to reduce trachoma through increased donations, resulting in a roughly 50 percent decrease in the number of people at risk of trachoma worldwide today compared to 2011.
Read more: http://www.worldpharmanews.com/pfizer/4444-pfizer-announces-extension-of-zithromax-antibiotic-donation-program-through-2025-to-help-eliminate-world-s-leading-infectious-cause-of-blindness